Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial NPt-Ca

Brain Tumor, Pediatric, Recurrent Clinical Trial

Official title:

Pilot Study of the Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial Platinum Acetylacetonate (1% wt) Supported by Sol-gel Technology Functionalized Titania (NPt-Ca)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03250520
• Other study ID #: HIM 2017-072
• Status: Completed
• Phase: Early Phase 1
• Start date: September 1, 2017
• Est. completion date: June 28, 2022

Study information

• Verified date: February 2023
• Source: Hospital Infantil de Mexico Federico Gomez
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Protocol is a pilot, clinical interventional study to selected patients between five and fourteen years of both sexes, carriers of the diagnosis of glioma brain stem and high grade recurrent in the central nervous system tumors, in whom there has been no response to conventional-based surgery/radiation/chemotherapy treatment or whose location does not allow treatment with conventional measures, and that already have an indication for a neurosurgical palliative procedure. It will be a close pharmacovigilance on possible adverse effects related to the nanomaterial based on the profile of cisplatin (chemotherapeutic platinum derivative), since documented toxicity data are not counted for NPt-Ca. Quality of life will be documented with PedsQL Cancer Module© and tumor size by magnetic resonance brain images.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: June 28, 2022
• Est. primary completion date: January 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 14 Years

Eligibility

Inclusion Criteria:

• Histopathological diagnosis or MRI of the brain stem or tumor of recurrent high-grade glioma.

• Indication of palliative surgical treatment by neurosurgery.

• Good general condition, enabling the realization of surgical treatment.

• Scale Lansky > 20)

• conventional treatment (surgery, radiotherapy, and chemotherapy) failed or not applicable to the patient.

Exclusion Criteria:

• Patients with emerging infectious diseases or fever in the last 72 hours prior to placement of the NPt-Ca.

• Patients whose parents/carers do not authorize expressly the realization of procedure with knowledge of its experimental nature, are not agreed or established their commitment to meet follow-up parameters established by this Protocol.

• Patients with surgical complications prior to placement of the NPt-Ca.

• Patients in which the size and location of the lesion do not allow their surgical approach or an increase in volume by infiltration of the lesion with 3 ml of volume of NPt-Ca.

• Patient whose neurological condition do not allow the implementation of MRI without anesthesia.

Related Conditions & MeSH terms

• Brain Neoplasms
• Brain Tumor, Pediatric, Brainstem Glioma
• Brain Tumor, Pediatric, Recurrent
• Glioma
• Neoplasms
• Recurrence

Intervention

Drug:
• Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania
Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.

Locations

Country	Name	City	State
Mexico	Hospital Infantil de Mexico Federico Gomez	DF

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Infantil de Mexico Federico Gomez

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the quality of life using the PedsQL Cancer Module©	Measures of the change of quality of life pre and after the administration of NPt-Ca using the questionnaire PedsQL Cancer Module©	Preoperative and at 1.3, 6, 12, 18 and 24 months.
Primary	Change in tumor size	Change in tumor size after the administration of NPt-Ca using volumetric measures on the brain magnetic resonance.	Immediate, 1, 2, 3, 6, 8, 10, 12, 18 and 24 months.